PL3618827T3 - Wytwarzanie trans-[tetrachlorobis(1h-indazolo)rutenianu (iii)] i jego kompozycji - Google Patents

Wytwarzanie trans-[tetrachlorobis(1h-indazolo)rutenianu (iii)] i jego kompozycji

Info

Publication number
PL3618827T3
PL3618827T3 PL18794220.6T PL18794220T PL3618827T3 PL 3618827 T3 PL3618827 T3 PL 3618827T3 PL 18794220 T PL18794220 T PL 18794220T PL 3618827 T3 PL3618827 T3 PL 3618827T3
Authority
PL
Poland
Prior art keywords
tetrachlorobis
ruthenate
indazole
trans
compositions
Prior art date
Application number
PL18794220.6T
Other languages
English (en)
Polish (pl)
Inventor
Tomas Vojkovsky
Kevin Sill
Adam Carie
Original Assignee
Bold Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bold Therapeutics Inc. filed Critical Bold Therapeutics Inc.
Publication of PL3618827T3 publication Critical patent/PL3618827T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046—Ruthenium compounds
    • C07F15/0053—Ruthenium compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL18794220.6T 2017-05-05 2018-05-07 Wytwarzanie trans-[tetrachlorobis(1h-indazolo)rutenianu (iii)] i jego kompozycji PL3618827T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762501984P 2017-05-05 2017-05-05
PCT/US2018/031436 WO2018204930A1 (en) 2017-05-05 2018-05-07 Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof

Publications (1)

Publication Number Publication Date
PL3618827T3 true PL3618827T3 (pl) 2024-01-22

Family

ID=64016742

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18794220.6T PL3618827T3 (pl) 2017-05-05 2018-05-07 Wytwarzanie trans-[tetrachlorobis(1h-indazolo)rutenianu (iii)] i jego kompozycji

Country Status (11)

Country Link
US (5) US10611787B2 (enExample)
EP (3) EP3618827B1 (enExample)
JP (4) JP7183253B2 (enExample)
CN (2) CN117462558A (enExample)
AU (2) AU2018263965B2 (enExample)
CA (1) CA3062369A1 (enExample)
ES (1) ES2959891T3 (enExample)
PL (1) PL3618827T3 (enExample)
RU (1) RU2019138773A (enExample)
SG (1) SG11201910043PA (enExample)
WO (1) WO2018204930A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3618827B1 (en) * 2017-05-05 2023-07-26 Bold Therapeutics Inc. Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)]and compositions thereof
US20230024119A1 (en) * 2019-12-05 2023-01-26 Bold Therapeutics, Inc. Combined use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] and etomoxir for treating cancers
WO2021195763A1 (en) * 2020-03-30 2021-10-07 Bold Therapeutics Inc. Antiviral ruthenate(iii) therapeutics
EP4247413A4 (en) * 2020-11-18 2024-10-09 Bold Therapeutics Inc. USE OF SODIUM TRANS-[TETRACHLORIDOBIS(1H-INDAZOLE)RUTHENATE(III)] FOR THE TREATMENT OF CANCERS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612291A1 (de) * 1996-03-28 1997-10-02 Bernhard K Prof Dr Dr Keppler Arzneimittelzubereitungen enthaltend tumorhemmend wirkende Ruthenium(III)-Komplexe
DE10103565B4 (de) * 2001-01-26 2007-06-14 Faustus Forschungs Cie. Translational Cancer Research Gmbh Zusammensetzungen, enthaltend einen Ruthenium(III)-komplex und einen Heterocyclus
ES2441262T3 (es) 2007-06-11 2014-02-03 Niiki Pharma Inc. Método de fabricación de un complejo de rutenio
EP2509599B1 (en) * 2009-12-11 2014-08-13 Niiki Pharma Inc. Method for treating pancreatic cancer
JP5826259B2 (ja) 2010-06-22 2015-12-02 フイルメニツヒ ソシエテ アノニムFirmenich Sa ルテニウムベース錯体
WO2012012305A2 (en) 2010-07-18 2012-01-26 Niiki Pharma Inc. Combination therapy using a ruthenium complex
US10766915B2 (en) 2013-03-15 2020-09-08 Sherri Ann McFARLAND Metal-based coordination complexes as photodynamic compounds and their use
CN103601759B (zh) 2013-10-18 2015-08-19 武汉利宝瑞医药科技有限公司 一种用于治疗肿瘤的钌(iii)络合物的制备方法
US10342801B2 (en) * 2015-06-23 2019-07-09 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
EP3618827B1 (en) * 2017-05-05 2023-07-26 Bold Therapeutics Inc. Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)]and compositions thereof

Also Published As

Publication number Publication date
EP4245305A2 (en) 2023-09-20
EP3618827C0 (en) 2023-07-26
US20180327435A1 (en) 2018-11-15
EP4245305A3 (en) 2023-10-04
SG11201910043PA (en) 2019-11-28
EP3618827A4 (en) 2020-09-02
EP4245305C0 (en) 2025-10-08
RU2019138773A (ru) 2021-06-08
ES2959891T3 (es) 2024-02-28
AU2018263965A1 (en) 2019-11-21
JP7183253B2 (ja) 2022-12-05
JP7698083B2 (ja) 2025-06-24
US12415825B2 (en) 2025-09-16
WO2018204930A1 (en) 2018-11-08
US20200262855A1 (en) 2020-08-20
JP7433402B2 (ja) 2024-02-19
US20210277040A1 (en) 2021-09-09
EP4635503A2 (en) 2025-10-22
US11739111B2 (en) 2023-08-29
JP2023016867A (ja) 2023-02-02
US10611787B2 (en) 2020-04-07
JP2024045436A (ja) 2024-04-02
EP3618827A1 (en) 2020-03-11
EP4635503A3 (en) 2025-10-29
CN111372939A (zh) 2020-07-03
US20230357297A1 (en) 2023-11-09
CN111372939B (zh) 2023-11-07
US20260042792A1 (en) 2026-02-12
JP2020518676A (ja) 2020-06-25
CA3062369A1 (en) 2018-11-08
AU2018263965B2 (en) 2024-02-29
AU2024203511A1 (en) 2024-06-20
RU2019138773A3 (enExample) 2022-02-01
EP3618827B1 (en) 2023-07-26
AU2024203511B2 (en) 2026-03-19
JP2025123344A (ja) 2025-08-22
CN117462558A (zh) 2024-01-30
EP4245305B1 (en) 2025-10-08
US11040993B2 (en) 2021-06-22

Similar Documents

Publication Publication Date Title
IL278829A (en) The compositions containing bis-(fluoroalkyl)-1,4 benzodiazepines and immunotherapeutic substances and methods of using them
MX2020006595A (es) Oxadiazoles fungicidas.
IL271604B (en) Fungicides
WO2016011306A3 (en) Terminal modifications of polynucleotides
HUE054042T2 (hu) Pirazolvegyületek és eljárás a vegyületek elõállítására és alkalmazásuk
IL271891A (en) Stable preparations containing cannabinoids
ZA201808057B (en) Synthesis of indazoles
SG11202003348YA (en) Etching compositions
WO2015120062A8 (en) Therapeutic compounds and compositions
IL262413B (en) Synthesis of indazoles
IL273259A (en) Production of pharmaceutical preparations
ZA202004532B (en) Compositions for the management of hyperglycemia and related conditions
PL3713416T3 (pl) Kompozycje grzybobójcze
EP3318080A4 (en) User equipment adaptation of reporting triggers based on active set size
IL261384A (en) Use of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] for the treatment of cancer
IL271892A (en) Stable preparations containing cannabinoids
EP4245305C0 (en) MANUFACTURE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] AND COMPOSITIONS THEREOF
EP3712133A4 (en) SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION WITH IT
IL276410A (en) Pyrazole compounds and their preparation
IL272999A (en) A preparation for use in the treatment of eczema of the skin
SG11202105114PA (en) Storage-stable form of 3-methylthiopropionaldehyde
HK40030313A (en) Glycan compositions and methods of use
CN302518400S (zh) 可视voip电话(jtchipp3d)
CN302283308S (zh) 电子设备壳
CN302112913S (zh) 医护终端